← FDA DRUG APPROVALS
FDA ANDA · ANDA217830
ABACAVIR, DOLUTEGRAVIR AND LAMIVUDINE
Sponsor: MACLEODS PHARMACEUTICALS LTD
APPLICATION
ANDA217830
TYPE
ANDA
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)
Products
ABACAVIR, DOLUTEGRAVIR AND LAMIVUDINENone (Tentative Approval)
ABACAVIR, DOLUTEGRAVIR, LAMIVUDINE 30MG · TABLET
ABACAVIR, DOLUTEGRAVIR AND LAMIVUDINENone (Tentative Approval)
ABACAVIR, DOLUTEGRAVIR, LAMIVUDINE 5MG · TABLET
Approval history
2025-09-17UNKNOWN · Original · standardTA
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.